Hospital
Pih Health Downey Hospital
Pih Health Downey Hospital was paid $25.37M by Medicaid between Jan 2018 and Nov 2024, across 256 billing codes. Its largest line is 0450, Emergency room services — 20% of everything it billed.
33Billing provider infoPIH HEALTH DOWNEY HOSPITAL
DOWNEY, CA 90241
DOWNEY, CA 90241
33aNPI1265433551assigned 08/09/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$25.37M
24GClaims1,095,256
24DCodes billed256
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#103 of 410
Median peer was paid$6.90M
This provider vs. median3.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 164,678 | $2.95M | |
| 2019 | 156,979 | $4.31M | |
| 2020 | 125,551 | $2.71M | |
| 2021 | 133,859 | $3.46M | |
| 2022 | 163,568 | $4.36M | |
| 2023 | 186,258 | $4.49M | |
| 2024incomplete | 164,363 | $3.10M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 20% | 128,088 | 116,397 | $5.15M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 6.6% | 9,733 | 9,395 | $1.68M |
| 0270 | 3.5% | 42,319 | 26,369 | $891K | |
| 70450 | Computed tomography, head or brain; without contrast material | 3.4% | 9,910 | 9,553 | $866K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.4% | 19,749 | 18,443 | $855K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 3.1% | 9,764 | 8,448 | $779K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 2.8% | 6,570 | 6,190 | $713K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.7% | 38,034 | 34,043 | $691K |
| 0250 | 2.1% | 33,987 | 20,623 | $536K | |
| 93975 | 2.0% | 3,476 | 3,328 | $501K | |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 1.8% | 4,719 | 4,461 | $450K |
| J3490 | Unclassified drugs | 1.7% | 53,284 | 29,485 | $430K |
244 more codes
| 80048 | Basic metabolic panel (calcium, ionized) | 1.6% | 59,892 | $417K |
| 0214 | 1.6% | 181 | $412K | |
| 71045 | Radiologic examination, chest; single view | 1.6% | 38,083 | $405K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.6% | 71,481 | $404K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.4% | 21,592 | $364K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.4% | 12,948 | $354K |
| Z7502 | 1.4% | 9,731 | $343K | |
| 0360 | 1.3% | 2,579 | $323K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.2% | 3,036 | $294K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.1% | 7,738 | $289K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | 1.1% | 6,362 | $285K |
| 99199 | Unlisted special service, procedure or report | 1.1% | 8,874 | $267K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,654 | $238K |
| 0300 | <1% | 640 | $237K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 3,423 | $208K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,697 | $208K |
| 99285 | Emergency room visit (most serious) | <1% | 574 | $202K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,776 | $189K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 10,859 | $187K |
| 0279 | <1% | 21,144 | $186K | |
| 84484 | <1% | 24,946 | $176K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 477 | $174K |
| 76830 | Ultrasound, transvaginal | <1% | 2,945 | $173K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 4,116 | $152K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 12,848 | $147K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,010 | $144K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,641 | $134K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 2,852 | $133K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 2,638 | $132K |
| 76801 | <1% | 3,037 | $129K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 307 | $123K |
| 80076 | <1% | 18,986 | $118K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,718 | $113K |
| 87634 | <1% | 2,632 | $110K | |
| 0121 | <1% | 38 | $104K | |
| 93971 | <1% | 1,439 | $104K | |
| 83690 | <1% | 21,143 | $102K | |
| 0710 | <1% | 3,496 | $100K | |
| 97161 | <1% | 3,732 | $93K | |
| 84703 | <1% | 15,424 | $84K | |
| 80053 | Comprehensive metabolic panel | <1% | 10,448 | $83K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 3,466 | $80K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 4,777 | $78K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 254 | $76K |
| 81003 | <1% | 42,106 | $71K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,433 | $67K |
| J2704 | Injection, propofol, 10 mg | <1% | 2,783 | $66K |
| 72100 | <1% | 2,790 | $66K | |
| 0160 | <1% | 811 | $66K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 11,335 | $64K |
| 90715 | <1% | 2,214 | $64K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 10,164 | $64K |
| 70486 | <1% | 542 | $63K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 381 | $63K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 9,557 | $62K |
| E0114 | Crutches underarm, other than wood, adjustable or fixed, pair, with pads, tips and handgrips | <1% | 2,640 | $59K |
| 73610 | <1% | 2,878 | $58K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 9,658 | $58K |
| 93970 | <1% | 506 | $57K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,565 | $56K |
| 73630 | <1% | 2,975 | $56K | |
| 73562 | <1% | 3,065 | $54K | |
| 73130 | <1% | 2,578 | $54K | |
| 0301 | <1% | 952 | $54K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,311 | $53K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,314 | $53K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 11,214 | $51K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,696 | $50K |
| 83880 | <1% | 2,727 | $49K | |
| 73030 | <1% | 2,630 | $46K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 1,112 | $45K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,519 | $45K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 201 | $44K |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 1,184 | $44K |
| 81025 | <1% | 10,934 | $43K | |
| 0762 | <1% | 679 | $43K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 860 | $42K |
| 76642 | <1% | 640 | $39K | |
| 84702 | <1% | 3,793 | $38K | |
| 73110 | <1% | 1,894 | $37K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,124 | $37K |
| 76641 | <1% | 286 | $36K | |
| 87040 | <1% | 4,823 | $35K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,107 | $29K |
| 82947 | <1% | 9,373 | $28K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,731 | $28K |
| 82805 | <1% | 1,141 | $27K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,378 | $27K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 4,140 | $26K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 2,577 | $26K |
| 73080 | <1% | 1,225 | $25K | |
| 0320 | <1% | 790 | $25K | |
| 0750 | <1% | 183 | $25K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 142 | $24K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 360 | $23K |
| 74018 | <1% | 1,365 | $22K | |
| Z7610 | <1% | 3,377 | $22K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 241 | $22K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 797 | $19K |
| 87186 | <1% | 2,941 | $19K | |
| 83735 | <1% | 4,435 | $19K | |
| 76775 | <1% | 552 | $18K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 248 | $17K |
| 77066 | Tomosynthesis, mammo | <1% | 386 | $16K |
| 83605 | <1% | 2,187 | $15K | |
| 73502 | <1% | 675 | $15K | |
| 0730 | <1% | 344 | $14K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 272 | $14K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 212 | $13K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 269 | $13K |
| 73564 | <1% | 528 | $13K | |
| 85730 | <1% | 3,434 | $13K | |
| 12001 | <1% | 1,108 | $12K | |
| 88312 | <1% | 214 | $12K | |
| S3620 | Newborn metabolic screening panel, includes test kit, postage and the laboratory tests specified by the state for inclusion in this panel (e.g., galactose; hemoglobin, electrophoresis; hydroxyprogesterone, 17-d; phenylalanine (pku); and thyroxine, total) | <1% | 88 | $12K |
| 73140 | <1% | 931 | $12K | |
| 82948 | <1% | 3,973 | $12K | |
| 84100 | <1% | 3,888 | $11K | |
| 76870 | <1% | 324 | $11K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,866 | $11K |
| 10060 | <1% | 768 | $11K | |
| 72040 | <1% | 610 | $11K | |
| 71250 | <1% | 84 | $11K | |
| 85610 | <1% | 4,467 | $11K | |
| 84439 | <1% | 1,666 | $11K | |
| 0272 | <1% | 1,146 | $10K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 354 | $10K |
| 86328 | <1% | 327 | $10K | |
| 86901 | <1% | 3,906 | $10K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 440 | $9K |
| 86900 | <1% | 3,869 | $9K | |
| 73590 | <1% | 504 | $9K | |
| 12011 | <1% | 502 | $9K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,385 | $9K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,801 | $9K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,694 | $9K |
| 70496 | <1% | 61 | $9K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,919 | $8K |
| 81002 | <1% | 4,756 | $8K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,216 | $8K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,321 | $8K |
| 99000 | <1% | 2,795 | $7K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 309 | $7K |
| 27502 | <1% | 172 | $7K | |
| 73090 | <1% | 455 | $7K | |
| 85378 | <1% | 1,280 | $7K | |
| Z9725 | <1% | 156 | $7K | |
| 70498 | <1% | 44 | $7K | |
| 87807 | <1% | 838 | $7K | |
| 87077 | <1% | 1,236 | $6K | |
| 72072 | <1% | 298 | $6K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 700 | $6K |
| L1830 | Knee orthosis, immobilizer, canvas longitudinal, prefabricated, off-the-shelf | <1% | 112 | $6K |
| 85027 | <1% | 1,249 | $5K | |
| 93017 | <1% | 79 | $5K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,112 | $5K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 715 | $5K |
| 87210 | <1% | 1,534 | $5K | |
| 86850 | <1% | 1,236 | $4K | |
| 87486 | <1% | 198 | $4K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 553 | $4K |
| 87581 | <1% | 197 | $4K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 55 | $4K |
| 86140 | <1% | 1,132 | $4K | |
| 99070 | <1% | 1,174 | $4K | |
| 77065 | Tomosynthesis, mammo | <1% | 95 | $3K |
| 29515 | <1% | 495 | $3K | |
| 29125 | <1% | 555 | $3K | |
| 92523 | <1% | 57 | $3K | |
| 97165 | <1% | 162 | $3K | |
| 71101 | <1% | 136 | $3K | |
| 77062 | <1% | 229 | $3K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 4,508 | $3K |
| J1815 | Injection, insulin, per 5 units | <1% | 978 | $2K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 155 | $2K |
| A4649 | Surgical supply; miscellaneous | <1% | 2,808 | $2K |
| 29540 | <1% | 344 | $2K | |
| 76536 | <1% | 68 | $2K | |
| 71010 | <1% | 223 | $2K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 311 | $2K |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | <1% | 137 | $2K |
| 70491 | <1% | 13 | $2K | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 61 | $2K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 188 | $2K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 13 | $1K |
| 80061 | Lipid panel | <1% | 213 | $1K |
| P9021 | Red blood cells, each unit | <1% | 15 | $1K |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 85 | $1K |
| A9270 | Non-covered item or service | <1% | 3,539 | $1K |
| 87081 | <1% | 286 | $1K | |
| 87070 | <1% | 237 | $1K | |
| 82550 | <1% | 280 | $1K | |
| 0637 | <1% | 897 | $1K | |
| 0352 | <1% | 13 | $1K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 186 | $1K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 61 | $921.41 |
| 29530 | <1% | 218 | $904.82 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 122 | $816.28 |
| 93925 | <1% | 13 | $782.53 | |
| 96367 | <1% | 27 | $761.26 | |
| 82010 | <1% | 164 | $721.35 | |
| S0077 | Injection, clindamycin phosphate, 300 mg | <1% | 46 | $650.82 |
| 73660 | <1% | 52 | $628.74 | |
| A0429 | Emergency ambulance ride, basic life support | <1% | 20 | $615.01 |
| 27610 | <1% | 45 | $602.20 | |
| 94060 | <1% | 12 | $531.45 | |
| A4217 | Sterile water/saline, 500 ml | <1% | 89 | $521.65 |
| 93041 | <1% | 116 | $514.45 | |
| 94729 | <1% | 24 | $511.20 | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 59 | $501.26 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 38 | $488.32 |
| 29130 | <1% | 83 | $461.06 | |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | <1% | 505 | $404.51 |
| 90375 | <1% | 14 | $396.00 | |
| 94726 | <1% | 18 | $391.20 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 23 | $282.28 |
| 77061 | <1% | 24 | $268.05 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 68 | $225.31 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 64 | $199.01 |
| 29105 | <1% | 15 | $197.58 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 16 | $196.73 |
| 81001 | <1% | 486 | $186.54 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 50 | $186.45 |
| 85651 | <1% | 93 | $165.73 | |
| 73060 | <1% | 12 | $151.91 | |
| 70360 | <1% | 12 | $148.90 | |
| 51702 | <1% | 15 | $142.00 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 168 | $141.03 |
| 0370 | <1% | 28 | $105.74 | |
| 82140 | <1% | 15 | $101.91 | |
| 29505 | <1% | 25 | $101.88 | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 12 | $99.35 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 12 | $97.15 |
| 96376 | <1% | 28 | $72.90 | |
| 82272 | <1% | 51 | $69.09 | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 19 | $60.82 |
| 82553 | <1% | 12 | $48.60 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 19 | $42.48 |
| 0294 | <1% | 13 | $32.85 | |
| 99072 | <1% | 272 | $4.64 | |
| S9445 | Patient education, not otherwise classified, non-physician provider, individual, per session | 0% | 208 | $0.00 |
| 0760 | 0% | 86 | $0.00 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 14 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPONCE (AKA CARLSON), SUE (SPECIAL PROJECTS)
| Provider | Location | Paid |
|---|---|---|
| Pih Health Whittier Hospital | Whittier, CA | $26.12M |
| Pih Health Whittier Hospital | La Mirada, CA | $1.53M |
| Pih Health Whittier Hospital | La Mirada, CA | $91K |
| Pih Health Whittier Hospital | Whittier, CA | $12K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.